867 results on '"Rispens, Theo"'
Search Results
2. Immunogenicity of Therapeutic Proteins
3. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy
4. The unique properties of IgG4 and its roles in health and disease
5. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication
6. Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy
7. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
8. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis
9. Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
10. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study
11. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
12. Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling
13. Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines
14. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
15. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases
16. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
17. Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial
18. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
19. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
20. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
21. Human IgE does not bind to human FcRn
22. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
23. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
24. Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report
25. P137 Concentrations of subcutaneously administered belimumab in human breast milk in a woman with systemic lupus erythematosus: a case report
26. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
27. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication
28. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients
29. Belimumab concentration measurements using a homologous anti-idiotype immunoassay
30. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
31. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study
32. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients
33. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
34. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease:A nested case-control study
35. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
36. Next-generation rheumatoid factor assay provides improved predictive power for the development of arthritis in patients at risk.
37. Immunogenicity of Therapeutic Proteins
38. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study
39. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
40. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection
41. Early model-based precision-dosing at home to guide adalimumab therapy
42. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
43. Impact of structural modifications of IgG antibodies on effector functions
44. Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies
45. CD5L is a canonical component of circulatory IgM
46. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment
47. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
48. Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load
49. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration
50. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.